Epizyme, Inc.

Accent Therapeutics, Inc.

Other

Eisai R&d Management Co., Ltd.

Glaxosmithkline Intellectual Property Development Limited

Kenneth William Duncan

Richard Chesworth

Michael John Munchhof

Lei Jin

Kevin Wayne Kuntz

Paula Ann Boriack-Sjodin

Masashi Seki

Christine Klaus

Heike Keilhack

Sarah Kathleen Knutson

Natalie Warholic

Syuji Shirotori

Satoshi Kawano

Timothy James Nelson Wigle

Timothy J N Wigle

Edward James Olhava

Gideon Shapiro

Lorna Helen Mitchell

Oscar Miguel Moradei

John Emmerson Campbell

Brian Andrew Sparling

Andrew Stewart Tasker

Matthew H Daniels

Darren Martin Harvey

Gavin Whitlock

Elayne Penebre

Timothy James Wigle

Lawrence Alan Reiter

John W Lampe

Robert E Babine

Megan Alene Cloonan Foley

Maria Alejandra Raimondi

Michael Thomenius

James Edward John Mills

Olena I Barbash

Mary-Margaret Zablocki

Megan Alene Foley

Oscar Miguel Moradel

Provided are compounds of the Formula (IIIA): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.

Inhibitors of KIF18A and uses thereof

Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.

Inhibitors of RNA helicase DHX9 and uses thereof

The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Aryl-OR heteroaryl-substituted benzene compounds

Aryl-or heteroaryl-substituted benzene compounds

Provided are compounds of the Formula (IIB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.

Compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, G1, G2, Q, Q, Q, and (II) are defined as set forth in the specification, as are uses of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.

Substituted indoles and methods of use thereof

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

MYST family histone acetyltransferase inhibitors

The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.

Combination therapies with EHMT2 inhibitors

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 

PRMT5 inhibitors and uses thereof

Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.

PRMT5 inhibitors and uses therof

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 

Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof

Growing community of inventors

Westwood, MA, United States of America

Kenneth William Duncan